Skip to main content

Table 4 Clinical characteristics and prevalence of comorbidities in the three comorbidity clusters

From: Comorbidities in unclassifiable interstitial lung disease

 

Cluster 1:

(Few comorbidities)

n = 77

Cluster 2:

(Cardiovascular)

n = 85

Cluster 3:

(Emphysema)

n = 87

Age, years (IQR)

68.0 (57.0–75.0), p = 0.22

69.0 (58.0–75.0), p = 0.99

71.0 (61.0–77.0), p = 0.23

Male, %

59.7, p = 0.91

63.5, p = 0.45

57.5, p = 0.51

Never smokers, %

36.4, p = 0.78

37.8, p = 0.53

31.4, p = 0.37

Current smokers, %

13.0, p = 0.53

12.2, p = 0.37

19.8, p = 0.13

Former smokers, %

50.6, p = 0.86

50.0, p = 0.96

48.8, p = 0.83

Missing, %

0.0

3.5

1.2

Pack years (IQR)

20.0 (15.0–30.0), p = 0.18

25.5 (13.0–40.0), p = 0.47

35.0 (10.0–43.0), p = 0.56

Body mass index (SD)

27.2 (5.3), p = 0.14

29.8 (4.9), p = 0.001

26.8 (4.8), p = 0.03*

FVC, % predicted (SD)

77.4 (21.3), p = 0.52

71.1 (26.4), p = 0.03*

79.3 (24.8), p = 0.11

DLCO, % predicted (SD)

53.8 (20.5), p = 0.06

44.5 (19.7), p = 0.006*

51.6 (19.8), p = 0.36

6MWD, m (SD)

377.7 (123.6), p = 0.19

304.2 (139.5), p < 0.0001*

394.6 (127.2), p = 0.005

Total number of comorbidities, n (SD)

0.9 (1.1), p < 0.0001*

3.4 (2.0), p < 0.0001

2.0 (1.1), p = 0.41

Emphysema, %

5.7, p < 0.0001*

25.7, p = 0.01*

70.3, p < 0.0001

Pulmonary hypertension, %

3.9, p = 0.11

14.1, p = 0.01

5.7, p = 0.33

Venous thromboembolism, %

3.9, p = 0.22

11.8, p = 0.03

4.6, p = 0.31

Sleep apnea, %

2.6, p = 0.28

8.2, p = 0.07

3.4, p = 0.46

Coronary artery disease, %

22.1, p = 0.14

28.2, p = 0.0005

1.1, p < 0.0001*

Dyslipidemia, %

6.5, p = 0.06

20.0, p = 0.009

10.3, p = 0.46

Arterial hypertension, %

0.0, p < 0.0001*

63.5, p < 0.0001

50.6, p = 0.008

Atrial fibrillation, %

10.4, p = 0.46

7.1, p = 0.58

8.0, p = 0.87

Chronic heart failure, %

7.8, p = 0.56

8.2, p = 0.40

3.4, p = 0.16

Heart valve disease, %

3.9, p = 0.65

8.2, p = 0.07

2.3, p = 0.17

Cerebrovascular disease, %

7.8, p = 0.69

3.5, p = 0.14

9.2, p = 0.28

Chronic renal failure, %

1.3, p = 0.19

8.2, p = 0.005

1.1, p = 0.13

Diabetes, %

0.0, p < 0.0001*

55.3, p < 0.0001

0.0, p < 0.0001*

Osteoporosis, %

5.2, p = 0.22

8.2, p = 0.94

11.5, p = 0.20

Gastro-esophageal reflux disease, %

0.0, p < 0.0001*

51.8, p < 0.0001

2.3, p < 0.0001*

Thyroid disease, %

7.8, p = 0.56

9.4, p = 0.17

2.3, p = 0.05

Liver failure, %

1.3, p = 0.56

0.0, p = 0.31

1.1, p = 0.66

Lung cancer, %

0.0, p = 0.34

2.4, p = 0.049

0.0, p = 0.30

Cancer, %

1.3, p = 0.03*

4.7, p = 0.43

12.6, p = 0.003†

Depression, %

1.3, p = 0.01*

7.1, p = 0.81

13.8, p = 0.007†

  1. Data are presented as means with standard deviations (SD) or interquartile range (IQR) for continuous variables and frequencies for categorical variables. Significance levels for the comorbidities was based on comparison between the result in one cluster and the rest of the cohort (the two other clusters combined) using the t-test or Wilcoxon Mann–Whitney U test
  2. *Significantly lower or less frequent in this cluster compared with the rest of the cohort (the two other clusters combined). Significantly higher or more frequent in this cluster compared with the rest of the cohort (the two other clusters combined). FVC: Forced vital capacity, DLCO: diffusion capacity of the lung for carbon monoxide, 6MWD: distance walked during the 6-min walk test